Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02560220
Other study ID # TOL-1
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 5, 2015
Est. completion date April 18, 2017

Study information

Verified date July 2018
Source Heidelberg University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase- I clinical trial to determine safety and feasibilty of intravenous administration of mitomycin C-treated donor peripheral blood mononuclear cells in patients with chronic kidney disease stage KDIGO 4 or 5 (i.e. GFR 15-30 mL/min or < 15 mL/min) who receive a kidney transplant from a living donor.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date April 18, 2017
Est. primary completion date April 18, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Chronic kidney disease stage KDIGO 4 or 5

- First kidney transplant from a living donor

- Age = 18 years

- ABO compatible

- CDC-PRA < 20%

- No donor-specific antibodies

- Negative CDC and ELISA crossmatch

- Immunosuppression with cyclosporin A, EC-MPS and methylprednisolone

- Informed consent

- Adequate contraception (women with child bearing potential)

Exclusion Criteria:

- Psychiatric disorder

- Heart failure (NYHA III or IV)

- Severe liver disease

- Active hepatitis B or C or HIV infection

- Active bacterial, fungal or viral disease

- Malignancy or malignancy in the last 5 years before screening

- Preexisting immunosuppression

- Vaccination with a live vaccine in the last 3 months before screening

- S/p splenectomy

- Substance abuse

- Pregnancy or lactation

- Women: Child/pregnancy with the intended donor

- Allergy against the investigational drug or part of it

- Other diseases that prohibit participation in the study (in the opinion of the investigator)

- Participation in an other interventional study

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Mitomycin C-induced peripheral blood mononuclear cells (MICs)
MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor

Locations

Country Name City State
Germany University of Heidelberg Heidelberg Baden-Wuerttemberg

Sponsors (3)

Lead Sponsor Collaborator
Heidelberg University German Federal Ministry of Economics and Technology, WiSP GmbH

Country where clinical trial is conducted

Germany, 

References & Publications (4)

Dittmar L, Mohr E, Kleist C, Ehser S, Demirdizen H, Sandra-Petrescu F, Hundemer M, Opelz G, Terness P. Immunosuppressive properties of mitomycin C-incubated human myeloid blood cells (MIC) in vitro. Hum Immunol. 2015 Jul;76(7):480-7. doi: 10.1016/j.humimm.2015.06.008. Epub 2015 Jun 11. — View Citation

Kleist C, Sandra-Petrescu F, Jiga L, Dittmar L, Mohr E, Greil J, Mier W, Becker LE, Lang P, Opelz G, Terness P. Generation of suppressive blood cells for control of allograft rejection. Clin Sci (Lond). 2015 May;128(9):593-607. doi: 10.1042/CS20140258. — View Citation

Morath C, Schmitt A, Zeier M, Schmitt M, Sandra-Petrescu F, Opelz G, Terness P, Schaier M, Kleist C. Cell therapy for immunosuppression after kidney transplantation. Langenbecks Arch Surg. 2015 Jul;400(5):541-50. doi: 10.1007/s00423-015-1313-z. Epub 2015 Jun 17. Review. — View Citation

Terness P, Oelert T, Ehser S, Chuang JJ, Lahdou I, Kleist C, Velten F, Hämmerling GJ, Arnold B, Opelz G. Mitomycin C-treated dendritic cells inactivate autoreactive T cells: toward the development of a tolerogenic vaccine in autoimmune diseases. Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18442-7. doi: 10.1073/pnas.0807185105. Epub 2008 Nov 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome measure is the frequency of adverse events after intravenous administration of MICs within 30 days after transplantation. 30 days
Secondary Cumulative incidence of infection 30 days
Secondary Cumulative incidence of CMV reactivation 30 days
Secondary Number of patients with PTLD 30 days
Secondary Number of patients with delayed graft function 7 days
Secondary Number of patients with a pos. CDC and/or ELISA crossmatch day -1 before transplantation
Secondary Number of patients with DSA day -1 before transplantation and day 7 and 30 after transplantation
Secondary Incidence of biopsy-proven cellular rejection 30 days
Secondary Incidence of biopsy-proven antibody-mediated rejection 30 days
Secondary Number of patients with stable graft function (S-creatinine < 2mg/dL) 30 days
Secondary Patient and graft survival 30 days
See also
  Status Clinical Trial Phase
Completed NCT03246984 - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ N/A
Completed NCT02922361 - Spending and Outcomes for Complex Medicare Advantage Patients
Completed NCT02235571 - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients N/A
Completed NCT01922843 - A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis Phase 2
Completed NCT01930396 - Use of Tinzaparin for Anticoagulation in Hemodialysis Phase 4
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Not yet recruiting NCT01674660 - Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients N/A
Not yet recruiting NCT01157260 - The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Phase 4
Completed NCT01209403 - Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients Phase 4
Completed NCT00753116 - Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension Phase 1
Recruiting NCT00532688 - N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure Phase 2/Phase 3
Completed NCT00528788 - How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Phase 4
Completed NCT00534144 - Comparison Between Effects of Two Iron Preparations on Protein in the Urine Phase 1
Completed NCT00382044 - Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients N/A
Completed NCT00226902 - Vascular Reactivity in Kidney Disease Patients N/A
Recruiting NCT00235287 - Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Phase 4
Completed NCT00224081 - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) Phase 4
Completed NCT00071214 - Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis Phase 3
Completed NCT00049907 - Cardiac and Renal Disease Study (CARDS) N/A
Completed NCT00006297 - Risk Factors for CV Disease in a Dialysis Cohort N/A